期刊文献+

基于孕前优生平台的育龄女性假肥大型肌营养不良症携带者筛查模式 被引量:1

Carrier screening model for Duchenne muscular dystrophy for women of reproductive age based on a pre-pregnancy birth defect control platform
原文传递
导出
摘要 目的探索在孕前优生健康检查平台中建立育龄期女性假肥大型肌营养不良(Duchenne muscular dystrophy,DMD)致病基因携带者筛查模式,提高携带者的检出率。方法应用速率法/紫外分光光度法进行血清酶学检测,对2017年10月至2019年10月在杭州市参加国家免费孕前优生健康检查的61870名育龄女性进行肌酸磷酸肌酶(creatine kinase,CK)测定,针对CK高于阈值(≥200 U/L)者及有DMD家族史女性进行DMD基因检测。对确诊的携带者进行遗传咨询和随访。结果通过对61870名育龄女性CK检测,确定CK酶增高人数1078人,复查率57.33%(618/1078);对复查检测结果异常的120人进行基因检测,其中6人确定为DMD致病基因携带者;DMD家族史者基因检测33人,确定DMD致病基因携带者13人;筛查出1例DMD胎儿,经遗传咨询后孕妇选择终止妊娠。结论以国家免费孕前优生健康检查人群为主体,利用CK检测筛查DMD基因携带者是降低DMD患儿出生率的有效途径之一。 Objective To establish a screening model for females of reproductive age carrying Duchenne muscular dystrophy(DMD)variants based on a current community health examination platform.Methods A total of 61870 participants were recruited between October 2017 and October 2019.Serum creatine kinase(CK)was measured with a Roche Cobasc 701/702 using an enzymatic rate method.Genetic testing was offered to those with a CK level of≥200 U/L.For carriers of DMD variants,genetic counseling and follow up were provided.Results For the 61870 females participating in the program,1078 were found with raised serum CK(≥200 U/L),of which 618(57.33%)accepted CK re-measurement after at least a two-week interval.One hundred and twenty cases were found with sustained serum CK elevation,of which 6 were confirmed to be definite DMD carriers regardless of family history.Genetic testing was provided to 33 females with a family history for DMD,and 13 were determined as definite carriers.An affected fetus was detected by prenatal diagnosis.After genetic counseling,the parents had opted induced abortion.Conclusion Large-scale DMD carrier screening through a three-step approach based on the current community health examination platform is both feasible and cost effective.
作者 郑金仙 韩帅 叶文 姚树列 祁鸣 陈建芬 徐红 Zheng Jinxian;Han Shuai;Ye Wen;Yao Shulie;Qi Ming;Chen Jianfen;Xu Hong(Hangzhou Health Service Center for Children and Women,Hangzhou,Zhejiang 310006,China;Medical College of Zhejiang University,Hangzhou,Zhejiang 310058,China;Zhejiang Dian Diagnostics,Hangzhou,Zhejiang 310030,China)
出处 《中华医学遗传学杂志》 CAS CSCD 2021年第5期485-487,共3页 Chinese Journal of Medical Genetics
基金 杭州市科技计划引导项目(20181228Y20)。
关键词 假肥大型肌营养不良 育龄女性 筛查体系 肌酸磷酸激酶 携带者 Duchenne muscular dystrophy Reproductive age Screening Serum creatine kinase Carrier
  • 相关文献

参考文献5

二级参考文献29

  • 1Murugan S, Chandramohan A, Lakshmi BR. Use of multiplex ligation-dependent probe amplification (MLPA) for Duchenne muscular dystrophy (DMD) gene mutation analysis. Indian J Med Res,2010,132 : 303-311.
  • 2Hamed SA, Hoffman EP. Automated sequence screening of the entire dystrophin eDNA in Duchenne dystrophy: point mutation detection. AmJ Med Genet BNeuropsyehiatr Genet,2006,141B: 44-50.
  • 3Lira BC,Lee S,Shin JY,et al. Genetic diagnosis of Duchenne and Becket muscular dystrophy using next generation sequencing technology : comprehensive mutational search in a single platform. J Med Genet, 2011,48:731-736.
  • 4Magri F, Del Bo R, D'Angelo MG, et al. Clinical and molecular characterization of a cohort of patients with novel nucleotide alterations of the Dystrophin gene detected by direct sequencing. BMC Med Genet,2011,12:37.
  • 5Flanigan KM, Dunn DM, yon Niederhausern A, et al. Nonsense mutation-associated Beeker muscular dystrophy : interplay between exon definition and splicing regulatory elements within the DMDgene. Hum Mutat,2011,32:299-308.
  • 6Bovolenta M,Neri M,Fini S, et al. A novel custom high density- comparative genomic hybridization array detects common rearrangements as well as deep intronie mutations in dystrophinopathies. BMC Genomics, 2008,9 ; 572.
  • 7Zhang Z, Habara Y, Nishiyama A, et al. Identi{ication of seven novel cryptic exons embedded in the dystrophin gene and characterization of 14 cryptic dystrophin exons. J Hum Genet, 2007,52:607-617.
  • 8Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1 : diagnosis, and pharmaeological and psychosocial management [J]. Lancet Neurol, 2010, 9: 77-.93.
  • 9Laing NG, Davis MR, Bayley K, et al. Molecular diagnosis of Duchenne muscular dystrophy: past, present and future in relation to implementing therapies[J]. Clin Biochem Rev, 2011,32 :129-134.
  • 10Abbs S, Tuffery-Giraud S, Bakker E, et al. Best practice guidelines on molecular diagnostics in Duchenne/Becker muscular dystrophies[J]. Neuromuscul Disord, 2010, 20: 422-427.

共引文献70

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部